EMV Capital PLC - life sciences focused investor - Portfolio company ProAxsis plans to raise £800,000 via the issue of new shares. ProAxsis is a respiratory diagnostics company and a spin-out from Queens University Belfast. Proceeds will be divided as to £500,000 towards core business activities, and £300,000 towards advancing a COPD clinical study with Imperial College. In addition, ProAxsis says revenue rose 92% to £470,000 in 2024. EMV has a near 89% stake in ProAxsis which had a fair value of £8.0 million as at June 30, 2024.

Current stock price: 50.00 pence

12-month change: down 22%

Copyright 2025 Alliance News Ltd. All Rights Reserved.